Pan, ZiyanZerehpoosh, ShadiWang, Shu-ChiÖrmeci, NecatiKim, WonEslam, Mohammed2026-03-252026-03-252026Pan, Z., Zerehpoosh, S., Wang, S. C., Örmeci, N., Kim, W., Eslam, M. (2026). Beyond organ-specific therapies: A unified approach to multi-organ fibrosis. Drug Design, Development and Therapy, 20, pp. 1-14. https://doi.org/10.2147/DDDT.S5663191177-8881https://doi.org/10.2147/DDDT.S566319https://hdl.handle.net/20.500.13055/1368Organ fibrosis, characterized by excessive scarring of tissues in the liver, kidney, lung, and heart, poses a significant and growing global health challenge, resulting in considerable morbidity and mortality, with a lack of effective treatment options. Most research and drug development efforts have traditionally focused on individual organs in isolation. This review aims to provide a comprehensive perspective on multi-organ fibrosis, highlighting recent advances that clarify the complex cellular and molecular mechanisms involved in the liver, kidney, lung, and heart. It examines both common and organ-specific factors that drive fibrogenesis. Additionally, the review discusses the current and future landscape of antifibrotic therapies, including innovative approaches to developing pan-organ antifibrotic drugs. Challenges and future directions in the design of clinical trials are also addressed.eninfo:eu-repo/semantics/openAccessFibrosisAntifibrotic TherapyMulti-Organ DiseaseMyofibroblastExtracellular MatrixPrecision MedicineReview Article10.2147/DDDT.S56631920114Q1WOS:0016993172000012-s2.0-105030933285PMID: 4176926Q1